Multi-center, Randomized, Double-blind, Dose-finding, Phase 2a Clinical Trial to Evaluate the Effecacy and Safety of YD312 Tablet in Patients With Diabetic Macular Edema
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors YD Global Life Science
- 24 Sep 2019 Planned End Date changed from 8 Nov 2019 to 8 Dec 2019.
- 24 Sep 2019 Planned primary completion date changed from 16 Aug 2019 to 16 Nov 2019.
- 24 Sep 2019 Status changed from recruiting to active, no longer recruiting.